Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2000-11-15
pubmed:abstractText
Autologous peripheral blood stem cell (PBSC) transplantation is increasingly being used in patients with chronic lymphocytic leukemia (CLL). As the autografts are frequently contaminated with large numbers of tumor cells, we have prospectively investigated the feasibility and efficacy of ex vivo double purging of PBSC grafts in an open, nonrandomized, single-center phase I/II clinical study.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0301-472X
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1187-96
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:11027838-Adult, pubmed-meshheading:11027838-Antigens, CD34, pubmed-meshheading:11027838-B-Lymphocytes, pubmed-meshheading:11027838-Blood Component Removal, pubmed-meshheading:11027838-Feasibility Studies, pubmed-meshheading:11027838-Female, pubmed-meshheading:11027838-Flow Cytometry, pubmed-meshheading:11027838-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:11027838-Humans, pubmed-meshheading:11027838-Immunomagnetic Separation, pubmed-meshheading:11027838-Infection, pubmed-meshheading:11027838-Leukapheresis, pubmed-meshheading:11027838-Leukemia, Lymphocytic, Chronic, B-Cell, pubmed-meshheading:11027838-Male, pubmed-meshheading:11027838-Middle Aged, pubmed-meshheading:11027838-Prognosis, pubmed-meshheading:11027838-Prospective Studies, pubmed-meshheading:11027838-Treatment Outcome
pubmed:year
2000
pubmed:articleTitle
A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia.
pubmed:affiliation
Departments of Internal Medicine II, University of Kiel, Kiel, Germany. p.dreger@med2.uni-kiel.de
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I